You are viewing a preview of...

Infigratinib

Achondroplasia is a rare, genetic condition that affects bone growth. It is the most common type of skeletal dysplasia. Achondroplasia causes bone growth to slow down, especially in the long bones of the arms and legs. This causes short stature, shortened limbs, and other distinctive features.

We are committed to pursuing research to address the needs of the achondroplasia community

Our clinical program includes multiple studies that are grounded in learning more about achondroplasia and evaluating an oral treatment option for this skeletal dysplasia

What is being studied?

Genetic variants that cause fibroblast growth factor receptor 3 (FGFR3) overactivity can lead to skeletal conditions such as achondroplasia. We are studying whether an investigational agent (infigratinib) has the potential to improve

Log in or create a free account to continue reading